Klaria Interim Report Q3 2024

Klaria Interim Report Q3 2024

1 July - 30 September 2024

Third quarter of 2024

The group in total

- Net sales 0.0 MSEK (0.6 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 1 MSEK (7.4 MSEK)

- Profit after tax amounted to -7.9 MSEK (-10.8 MSEK)

- Earnings per share for the quarter amounted to -0.06 SEK (-0.10 SEK)

- Cash flow from operating activities amounted to -3.8 MSEK (-7.3 MSEK)

- Liquid assets on the balance sheet date amounted to 0.5 MSEK (2.3 MSEK)

- Equity as of September 30 amounted to 12.9 MSEK (50.7 MSEK)

The period January- September 2024

The group in total

- Net sales 0.0 MSEK (7.1 MSEK)

- Other income 0.0 MSEK (0.2 MSEK)

- R&D expenses for the quarter amounted to 2.5 MSEK (23.0 MSEK)

- Profit after tax amounted to -32.2 MSEK (-26.3 MSEK)

- Earnings per share for the period amounted to -0.26 SEK (-0.27 SEK)

- Cash flow from operating activities amounted to -13.2 MSEK (-18.6 MSEK)

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.